胰腺癌患者血清铁调素与BMP2、IL-6及血红蛋白表达的关系

Changes of serum hepcidin levels in patients with pancreatic cancer and its relationship with IL-6、BMP2 and hemoglobin

[目的]研究胰腺癌患者血清中铁调素(hepcidin)水平的变化,及其与白细胞介素-6(IL-6)、骨成型蛋白2(BMP2)及血红蛋白(Hb)间的关系。[方法]选取胰腺癌患者103例(胰腺癌组),另选取57例健康体检者作为正常对照组,应用酶联免疫吸附(ELISA)法检测2组血清中hepcidin、BMP2及IL-6的水平,同时收集2组血红蛋白的临床检测值。比较2组血清中hepcidin水平的差异,并分析胰腺癌患者血清hepcidin与IL-6、BMP2及Hb间的关系。[结果]胰腺癌组患者血清hepcidin和BMP2水平与正常对照组相比差异无统计学意义(P>0.05);胰腺癌患者血清hepcidin水平与IL-6、BMP2表达相关,与Hb不相关。[结论]胰腺癌患者血清hepcidin水平较正常人无明显改变,胰腺癌患者的贫血程度对血清hepcidin表达无明显影响,BMP2是反映hepcidin变化的重要因素。

[Objective]To study the changes of serum hepcidin level in pancreatic cancer patients and analyze its relationship with interleukin-6(IL-6),bone morphogenetic protein 2(BMP2)and hemoglobin(Hb).[Methods]We collected 103 cases of pancreatic cancer patients and 57 cases of normal people as the control group.The expressions of serum hepcidin, BMP2 and IL-6 in pancreatic cancer patients and the control group were measured by enzym-linked immunosorbent assay(ELISA).We compare the difference of serum Hepcidin level between the two groups and analyzed the relationship between serum hepcidin and IL-6,BMP2,Hb and tumor stage.[Results]There was no significant difference in serum hepcidin level between pancreatic cancer patients and normal control group(P> 0.05).Serum hepcidin level was statistically correlated with IL-6 and BMP2 in pancreatic cancer patients, but not with Hb level or tumor stage.[Conclusion]The level of serum Hepcidin in patients with pancreatic cancer has no significant change compared with normal controls.The degree of anemia in patients with pancreatic cancer has no significant influence on the expression of serum hepcidin.BMP2 is an important factor that can respond to the change of hepcidin.